Gaylen M Zentner
Pharmacy in Salt Lake City, UT

6589549, Jul 8, 2003

Jul 13, 2001

09/906041

Chung Shih - Salt Lake City UT
Gaylen Zentner - Salt Lake City UT

Macromed, Incorporated - Sandy UT

A61F 200

424426, 424486, 424489, 424501, 5147723

A composition and method for releasing a bio-active agent or a drug within a biological environment in a controlled manner is disclosed. The composition is a dual phase polymeric agent—delivery composition comprising a continuous biocompatible gel phase, a discontinuous particulate phase comprising defined microparticles and an agent to be delivered. A microparticle containing a bio-active agent is releasably entrained within a biocompatible polymeric gel matrix. The bioactive agent release may be contained in the microparticle phase alone or in both the microparticles and the gel matrix. The release of the agent is prolonged over a period of time, and the delivery may be modulated and/or controlled. In addition, a second agent may be loaded in some of the microparticles and/or the gel matrix.

6730327, May 4, 2004

Dec 20, 2002

10/327457

Gaylen M. Zentner - Salt Lake City UT
Jong-Seok Bark - Salt Lake City UT
Feng Liu - Salt Lake City UT

MacroMed, Inc. - Sandy UT

A61K 914

424489, 424484, 424486, 424488, 424499, 424501, 514772, 5147721, 5147722, 5147723

A polymer blend is prepared by dissolving chitosan and a second polymer in an acidic aqueous solution to form an aqueous polymer blend, dehydrating said aqueous polymer blend, and recovering said polymer blend. The second polymer may be selected from the group consisting of polyether glycols including polyethylene glycols; cellulose esters including cellulose acetate; poloxamers; polysaccharides including dextran and guar; polyvinylpyrrolidones; polyvinyl alcohols; and mixtures or copolymers thereof. These polymer blends swell in an acidic environment and deswell in a more neutral or basic environment. This technology is valuable for the dispensing of biologically active material or drugs into a surrounding environment, especially the environment as is found in the gastrointestinal tract. Since the various polymer blends of the present invention are not covalently or ionically crosslinked, but are physically combined, each polymer in the physical blend maintains its original chemical structure, and therefore, is safe for oral administration.

6592899, Jul 15, 2003

Oct 3, 2001

09/971082

Kirk Dee Fowers - Layton UT
Gaylen M. Zentner - Salt Lake City UT
Chung Shih - Sandy UT

Macromed Incorporated - Sandy UT

A61K 914

424486, 424426, 424444, 424430, 424434, 424449, 424484, 525411, 525413, 525415

Polymeric compositions having improved capability of solubilizing a drug in a hydrophilic environment to form a solution, comprising: a biodegradable polyester oligomer; and biodegradable AB-type, ABA-type, or BAB-type block copolymers are disclosed. The copolymers are comprised of about 50. 1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and about 35 to 49. 9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 2400 to 4999. The biodegradable polyester oligomer of said composition is within a range of 0. 01% to 30% by weight of the total polymer mixture, and the content of the biodegradable AB-type, ABA-type, or BAB-type block copolymer is within a range of 70% to 99. 99% by weight of the total polymer mixture.

6117949, Sep 12, 2000

Oct 1, 1998

9/164865

Ramesh C. Rathi - Salt Lake City UT
Gaylen M. Zentner - Salt Lake City UT

Macromed, Inc. - Salt Lake City UT

C08G 6391, C08L 6700

525415

A water soluble biodegradable ABA- or BAB-type triblock polymer is disclosed that is made up of a major amount of a hydrophobic polymer made of a poly(lactide-co-glycolide) copolymer or poly(lactide) polymer as the A-blocks and a minor amount of a hydrophilic polyethylene glycol polymer B-block, having an overall weight average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the triblock polymer and a drug may be uniformly contained in an aqueous phase to form a drug delivery composition. At temperatures below the gelation temperature of the triblock polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, vaginal, transurethral, rectal, nasal, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel.

2004018, Sep 23, 2004

Dec 11, 2003

10/734740

Chung Shih - Sandy UT, US
Gaylen Zentner - Salt Lake City UT, US
Kirk Fowers - Layton UT, US

MacroMed, Incorporated.

A61K009/14

424/486000

Biodegradable ABA-type or BAB-type triblock copolymers are disclosed that, at functional concentrations, are capable of solubilizing drugs, especially hydrophobic drugs, in a hydrophilic environment to form a solution at temperatures relevant for parenteral and particularly for intravenous administration as well as all other routes of administration benefiting from an aqueous drug solution. The copolymers are comprised of about 50.1 to 65% by weight of biodegradable hydrophobic A polymer block(s) comprising a biodegradable polyester, and about 35 to 49.9% by weight of a biodegradable hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the triblock copolymer has a weight-averaged molecular weight of between about 1500 to 3099 Daltons.

2003022, Dec 11, 2003

Jun 11, 2002

10/167768

Chung Shih - Sandy UT, US
Gaylen Zentner - Salt Lake City UT, US

A61K009/14

424/486000

A composition having enhanced reconstitution properties and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative; and wherein the biodegradable block copolymer drug carrier is soluble in an aqueous solution and in the liquid reconstitution enhancing and enabling agent.

2010007, Mar 25, 2010

Nov 30, 2009

12/627175

Chung Shih - Sandy UT, US
Gaylen M. Zentner - Salt Lake City UT, US

A61K 47/30, A61K 31/337, A61P 35/00

514449, 5147721

An improved drug delivery composition and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered as is or after being be dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal systems.

2011011, May 12, 2011

Apr 30, 2010

12/771621

Gaylen M. Zentner - Salt Lake City UT, US
James C. McRea - Salt Lake City UT, US
Mark S. Williams - Salt Lake City UT, US
Tracy Annette Powers - Saint Louis MO, US

Myriad Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31/192, A61K 9/28, A61P 25/28

424465, 514570

The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.